ALN-F1202 Investigational factor XII-silencing RNAi therapy licensed to Regeneron, undergoing Phase 1 clinical development in healthy volunteers within its hematology program.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-F1202.
Add it to your Products I use list and share why you use it.